🎉 M&A multiples are live!
Check it out!

Amicus Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Amicus Therapeutics and similar public comparables like Vivoryon Therapeutics, Julphar, and Benevolent AI.

Amicus Therapeutics Overview

About Amicus Therapeutics

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.


Founded

2002

HQ

United States of America
Employees

499

Website

amicusrx.com

Financials

LTM Revenue $558M

LTM EBITDA $59.6M

EV

$2.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Amicus Therapeutics Financials

Amicus Therapeutics has a last 12-month revenue of $558M and a last 12-month EBITDA of $59.6M.

In the most recent fiscal year, Amicus Therapeutics achieved revenue of $528M and an EBITDA of $29.4M.

Amicus Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Amicus Therapeutics valuation multiples based on analyst estimates

Amicus Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $399M $528M XXX XXX XXX
Gross Profit $291M $362M XXX XXX XXX
Gross Margin 73% 69% XXX XXX XXX
EBITDA -$92.1M $29.4M XXX XXX XXX
EBITDA Margin -23% 6% XXX XXX XXX
Net Profit -$237M -$152M XXX XXX XXX
Net Margin -59% -29% XXX XXX XXX
Net Debt $243M $141M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Amicus Therapeutics Stock Performance

As of April 15, 2025, Amicus Therapeutics's stock price is $7.

Amicus Therapeutics has current market cap of $2.1B, and EV of $2.3B.

See Amicus Therapeutics trading valuation data

Amicus Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.3B $2.1B XXX XXX XXX XXX $-0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Amicus Therapeutics Valuation Multiples

As of April 15, 2025, Amicus Therapeutics has market cap of $2.1B and EV of $2.3B.

Amicus Therapeutics's trades at 4.0x LTM EV/Revenue multiple, and 37.9x LTM EBITDA.

Analysts estimate Amicus Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Amicus Therapeutics and 10K+ public comps

Amicus Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.3B XXX XXX XXX
EV/Revenue 4.3x XXX XXX XXX
EV/EBITDA 76.8x XXX XXX XXX
P/E -36.8x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -60.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Amicus Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Amicus Therapeutics Valuation Multiples

Amicus Therapeutics's NTM/LTM revenue growth is 20%

Amicus Therapeutics's revenue per employee for the last fiscal year averaged $1.1M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Amicus Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Amicus Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Amicus Therapeutics and other 10K+ public comps

Amicus Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 32% XXX XXX XXX XXX
EBITDA Margin 6% XXX XXX XXX XXX
EBITDA Growth -132% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 26% XXX XXX XXX XXX
Revenue per Employee $1.1M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 21% XXX XXX XXX XXX
Opex to Revenue 84% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Amicus Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Amicus Therapeutics M&A and Investment Activity

Amicus Therapeutics acquired  XXX companies to date.

Last acquisition by Amicus Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Amicus Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Amicus Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Amicus Therapeutics

When was Amicus Therapeutics founded? Amicus Therapeutics was founded in 2002.
Where is Amicus Therapeutics headquartered? Amicus Therapeutics is headquartered in United States of America.
How many employees does Amicus Therapeutics have? As of today, Amicus Therapeutics has 499 employees.
Who is the CEO of Amicus Therapeutics? Amicus Therapeutics's CEO is Mr. Bradley L. Campbell.
Is Amicus Therapeutics publicy listed? Yes, Amicus Therapeutics is a public company listed on NAS.
What is the stock symbol of Amicus Therapeutics? Amicus Therapeutics trades under FOLD ticker.
When did Amicus Therapeutics go public? Amicus Therapeutics went public in 2007.
Who are competitors of Amicus Therapeutics? Similar companies to Amicus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Amicus Therapeutics? Amicus Therapeutics's current market cap is $2.1B
What is the current revenue of Amicus Therapeutics? Amicus Therapeutics's last 12-month revenue is $558M.
What is the current EBITDA of Amicus Therapeutics? Amicus Therapeutics's last 12-month EBITDA is $59.6M.
What is the current EV/Revenue multiple of Amicus Therapeutics? Current revenue multiple of Amicus Therapeutics is 4.0x.
What is the current EV/EBITDA multiple of Amicus Therapeutics? Current EBITDA multiple of Amicus Therapeutics is 37.9x.
What is the current revenue growth of Amicus Therapeutics? Amicus Therapeutics revenue growth between 2023 and 2024 was 32%.
Is Amicus Therapeutics profitable? Yes, Amicus Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.